Arctoris was featured in Forbes following its early recognition as a trailblazer in a brand new field: the cloud lab for cancer research. The article explored how Arctoris was reimagining the traditional molecular biology laboratory, where researchers typically spend the majority of their day on manual, repetitive tasks such as pipetting and labelling, leaving little time for the creative scientific thinking that drives real breakthroughs.
The Arctoris model flips this on its head. Advanced robotics carry out the work and high-quality data is delivered directly to the scientist. Forbes drew a compelling analogy to the launch of Amazon Web Services, noting that just as AWS transformed how companies build digital infrastructure, Arctoris was set to do the same for life science research, removing the need for costly in-house lab setups and enabling a far more agile approach to experimentation.
The feature also highlighted a critical issue in the industry: the reproducibility crisis. Studies by Bayer and Amgen had demonstrated that up to 89% of published research findings could not be reproduced by independent third parties. Arctoris was presented as a direct response to this challenge, with its use of validated reagents, standardised protocols, transparent audit trails and built-in quality controls at every step of the experimental process.